ChromaDex Corporation completed a comprehensive corporate rebranding to Niagen Bioscience, Inc. with new ticker symbol NAGE, while delivering solid financial growth across key metrics.
The name change from ChromaDex to Niagen Bioscience represents a strategic repositioning around the company's flagship NAD+ precursor ingredient, potentially signaling a more focused business strategy. The rebrand coincides with strong operational performance, suggesting management confidence in the company's market position and growth trajectory.
The company demonstrated robust financial expansion with revenue growing 30% to $129.4M and gross profit increasing 35% to $83.2M, indicating improving operational efficiency. The balance sheet strengthened considerably with cash growing 64% to $44.5M and stockholders' equity expanding 66% to $76.5M, while total debt doubled to $5.0M from a low base. Inventory declined 37% to $9.2M, suggesting improved working capital management and demand fulfillment efficiency.
Debt increased 100% — substantial leverage increase; assess whether deployed for growth or covering losses.
Equity base grew 66% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Cash position surged 63.6% — strong cash generation or capital raise providing significant financial cushion.
Asset base grew 55.8% — expansion through organic growth, acquisitions, or capital deployment.
Current assets grew 51% — improving short-term liquidity or inventory/receivables build.
Capex reduced 43.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Inventory drawn down 36.7% — strong sell-through or deliberate destocking; watch for supply constraints.
Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.
Liabilities grew 34.7% — significant increase in debt or obligations, assess impact on financial flexibility.
Revenue growing 29.9% — solid top-line momentum, watch margins for quality of growth.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →